Other
Cytophage Announces the Commercialization of OvaPhage in Canada Through W.L.T. Distributors Inc.

CYTO · Price
Executive Summary
- Cytophage Technologies announced a distribution agreement with W.L.T. Distributors Inc. to sell its newly approved bacteriophage product, OvaPhage, across Canada.
- Health Canada issued a Letter of No Objection (LONO) for OvaPhage, marking a key regulatory milestone and enabling commercial sales in the Canadian egg industry.
- The partnership leverages WLT’s extensive poultry‑industry network to accelerate market adoption and improve food safety by reducing Salmonella on eggshells.
Key Details
- Distribution Partner: W.L.T. Distributors Inc. (Manitoba‑based agricultural supply company).
- Product: OvaPhage – a bacteriophage solution designed to lower Salmonella load on egg shells, offering an alternative to chemical cleaning methods.
- Regulatory Milestone: Received Health Canada’s Letter of No Objection (LONO), one of the first approvals for a commercial bacteriophage product of this type in Canada.
- Market Scope: Nationwide distribution across Canada; early adopters identified and packaging/labeling work underway.
- Industry Context: Canadian egg production totaled >915 million dozen eggs in 2024 (Statistics Canada). Reducing Salmonella aligns with food‑safety goals and consumer demand for antibiotic‑free products.
- Strategic Rationale (CEO Quote): “Our strength lies in developing scientifically advanced bacteriophage solutions… WLT provides efficient, cost‑effective marketing and distribution services… an ideal partnership.” – Dr. Steven Theriault, CEO, Cytophage Technologies.
- Partner Statement: “Given the challenges our industry faces today, it is critical we use innovative products that are both sustainable now and adaptable well into the future.” – James Hokanson, COO, WLT.
Notable Quotes
- “Cytophage is excited to have WLT Distributors on board to sell OvaPhage in Canada,” – Dr. Steven Theriault, CEO, Cytophage Technologies.
- “We have been following Cytophage’s progress from R&D to commercialization and are thrilled to work with their team on sales and distribution.” – James Hokanson, COO, WLT.
More from Cytophage Technologies Ltd.
May 22, 2026 · 19:00